EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 4.0

LUNAR : a randomized Phase 2 study of 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)

Ting Martin Ma iD, Johannes Czernin, Carol Felix, Rejah Alano, Holly Wilhalme, Luca Valle, Michael L Steinberg, Magnus Dahlbom, Robert E Reiter, Matthew B Rettig, Minsong Cao, Jeremie Calais und 1 weitere

BJU International · 2023

DOI: 10.1111/bju.15988 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift BJU International, 2023. Verfasst von Ting Martin Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective To assess the efficacy of 177 Lu‐PNT2002, a novel radiolabelled small molecule that binds with high affinity to prostate‐specific membrane antigen (PSMA), in combination with stereotactic body radiotherapy (SBRT) to all sites of metastasis, vs SBRT alone, in men with oligorecurrent metastatic hormone‐sensitive prostate cancer (mHSPC). Patients and Methods The 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR) trial is an open‐label, randomized, stratified, two‐arm, single‐centre, Phase 2 trial to compare the efficacy and safety of neoadjuvant 177 Lu‐PNT2002 plus SBRT vs SBRT alone in men with oligorecurrent mHSPC. Key eligibility criteria include one to five lesions identified on a PSMA positron emission tomography (PET)/computed tomography (CT) scan centrally reviewed by a board‐certified nuclear medicine physician. Key exclusion criteria include castrate‐resistant disease, de novo oligometastatic disease and receipt of androgen deprivation therapy (ADT) within 6 months of trial enrolment. The trial aims to enrol 100 patients who will be centrally randomized to one of the two treatment arms, in a 1:1 ratio. Patients in the control arm receive SBRT to all sites of disease. Patients in the experimental arm receive two cycles of neoadjuvant 177 Lu‐PNT2002 (6.8 GBq) 6–8 weeks apart, followed by an interval PSMA PET/CT in 4–6 weeks and dose‐adapted SBRT to all sites of disease 1–2 weeks later. The primary endpoint is progression‐free survival. Secondary endpoints are radiographic and prostate‐specific antigen‐based progression, acute and late physician‐scored toxicity, patient‐reported quality of life, ADT‐free survival, time to progression, overall survival, locoregional control, and duration of response. Enrolment in the study commenced in September 2022. Results and Conclusions The addition of 177 Lu‐PNT2002 to metastasis‐directed therapy alone may potentially further forestall disease progression. The results of this Phase 2 trial will determine, for the first time in a randomized fashion, the added benefit of 177 Lu‐PNT2002 to SBRT in patients with oligorecurrent mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansLutetiumPositron Emission Tomography Computed TomographyQuality of LifeNeoadjuvant TherapyAndrogen AntagonistsProstate-Specific AntigenRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

#ProstateCancer177Lu-PNT2002lutetium-177metastatic hormone-sensitive prostate canceroligorecurrentprogression-free survivalprostate cancerprostate-specific membrane antigenstereotactic body radiation therapytrial protocol

Substanzen

LutetiumAndrogen AntagonistsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California, Los Angeles, CA, USA.
  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
  • Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Department of Urology, University of California, Los Angeles, CA, USA.
  • Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

ORCID-Profile: Ting Martin Ma

Zitieren

APA

Ma, T. M., Czernin, J., Felix, C., Alano, R., Wilhalme, H., Valle, L., Steinberg, M. L., Dahlbom, M., Reiter, R. E., Rettig, M. B., Cao, M., Calais, J., & Kishan, A. U. (2023). LUNAR : a randomized Phase 2 study of 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU International. https://doi.org/10.1111/bju.15988

Vancouver

Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, et al. LUNAR : a randomized Phase 2 study of 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU International. 2023. doi:10.1111/bju.15988

BibTeX
@article{Ma2023,
  author = {Ma, Ting Martin and Czernin, Johannes and Felix, Carol and Alano, Rejah and Wilhalme, Holly and Valle, Luca and Steinberg, Michael L and Dahlbom, Magnus and Reiter, Robert E and Rettig, Matthew B and Cao, Minsong and Calais, Jeremie and Kishan, Amar U},
  title = {LUNAR : a randomized Phase 2 study of 177 Lutetium‐PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol)},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.15988}
}
Kostenlos starten →